Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Junshi Biosciences and Coherus to meet with US FDA to discuss 1L NSCLC BLA supplement submission SHANGHAI, China and REDWOOD CITY,